In TTP patients, TPE duration can be influenced by disease severity, ADAMTS13 activity, infection, earlier initiation, and adjunctive therapy (rituximab) [17]. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.